Prothena (PRTA)
(Real Time Quote from BATS)
$20.83 USD
-0.13 (-0.62%)
Updated Apr 23, 2024 11:44 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
PRTA 20.83 -0.13(-0.62%)
Will PRTA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PRTA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PRTA
J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?
CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
PRTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense
Arvinas, Inc. (ARVN) Soars 10.0%: Is Further Upside Left in the Stock?
Prothena's (PRTA) Update on Pipeline Progress Disappoints
Other News for PRTA
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
Prothena announces review on birtamimab mechanism
Labcorp expands Alzheimer's testing portfolio with new diagnostic
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Belite Bio, Inc. ADR (BLTE) and Prothena (PRTA)
Piper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)